C

CG Oncology
D

CGON

78.980
USD
0.67
(0.86%)
مغلق
حجم التداول
20,729
الربح لكل سهم
-4
العائد الربحي
-
P/E
-29
حجم السوق
7,000,816,818
المقالات
المزيد

العنوان: CG Oncology

القطاع: الرعاية الصحية
الصناعة: Biotechnology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.